Race Influences Survival in Uterine Cancer

Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

African-American women with uterine cancer have worse survival rates than white women who received similar treatment even though they had similar prognostic factors

WASHINGTON—African-American women with uterine cancer have worse survival rates than white women who received similar treatment even though they had similar prognostic factors, according to a review of four clinical trials (Cancer published online Sept. 25, 2006, DOI: 10.1002/cncr.22232; print issue date: Nov. 1, 2006). "While the causes of this survival difference remain to be elucidated, socioeconomic, biologic, and cultural etiologies may be involved," said G. Larry Maxwell, MD, of Walter Reed Army Medical Center.

The researchers analyzed data from 1,151 patients with stage III-IV or recurrent endometrial cancer enrolled in any of four randomized controlled treatment trials. After controlling for presentation and treatment, the researchers found that African-Americans had a 26% greater risk of death from uterine cancer than whites. "When response to treatment was analyzed, Blacks appeared to have lower tumor response to each of the chemotherapy regimens employed in the trials," Dr. Maxwell said. African-Americans survived a median 10.6 months vs 12.2 months for whites. At presentation, African-Americans were more likely to present with more serious disease, including papillary serous histology, stage IV disease, and high tumor grade.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content